<p>根据 Orca Wealth Management LLC 最近向证券交易委员会（SEC）提交的 13F 表格，该公司在第四季度购买了雅培（NYSE:ABT - 免费报告）的新头寸。该公司购买了 2,548 股该医疗产品制造商的股票，价值约为 288,000 美元。</p>
<p>获取 <strong>雅培</strong> 的提醒：</p>
<ul>
<li>雅培将在 2025 年超越医疗股票</li>
</ul>
<p>其他机构投资者和对冲基金最近也买卖了该公司的股票。Bath Savings Trust Co 在第四季度将其在雅培的股份提高了 3.7%。Bath Savings Trust Co 现在拥有 166,132 股雅培的股票，价值为 18,791,000 美元，此前在上个季度又购买了 5,881 股。Simplify Asset Management Inc.在第三季度将其在雅培的股份提高了 67.3%。Simplify Asset Management Inc.现在拥有 14,083 股雅培的股票，价值为 1,606,000 美元，此前在此期间又购买了 5,664 股。Pensionfund Sabic 在第四季度购买了雅培的新头寸，价值约为 2,828,000 美元。Sequoia Financial Advisors LLC 在第三季度将其在雅培的股份增加了 19.6%。Sequoia Financial Advisors LLC 现在拥有 193,764 股雅培的股票，价值为 22,091,000 美元，此前在此期间又购买了 31,720 股。最后，Tidal Investments LLC 在第三季度将其在雅培的持股提高了 30.5%。Tidal Investments LLC 现在拥有 107,308 股雅培的股票，价值为 12,234,000 美元，此前在上个季度又购买了 25,052 股。目前，75.18% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>华尔街分析师观点</h2>
<p>一些股票分析师最近对 ABT 股票发布了报告。摩根士丹利在 2023 年 10 月 17 日的研究报告中将雅培的目标价从 107.00 美元提高到 117.00 美元，并给予该股票 “持平” 评级。瑞穗在 2023 年 10 月 17 日的报告中将雅培的目标价从 115.00 美元提高到 130.00 美元，并给予该股票 “中性” 评级。巴克莱在周一的研究报告中重申了 “增持” 评级，并将雅培的目标价从 149.00 美元上调至 158.00 美元。杰富瑞金融集团在 2023 年 10 月 17 日的研究报告中将雅培的目标价从 120.00 美元提高到 125.00 美元，并给予该股票 “持有” 评级。最后，雷蒙德·詹姆斯在 2023 年 10 月 14 日的研究报告中重申了 “买入” 评级，并将雅培的目标价从 122.00 美元上调至 129.00 美元。四位投资分析师对该股票给予了持有评级，十三位分析师给予了买入评级。根据 MarketBeat.com 的数据，该公司的平均评级为 “适度买入”，平均目标价为 133.06 美元。</p>
<ul>
<li>这些是值得持有的顶级健康股票</li>
</ul>
<p><strong>查看我们对雅培的最新分析</strong></p>
<h2>雅培股票表现</h2>
<p>雅培（NYSE ABT）周三开盘价为 127.28 美元。该股票的 50 日移动平均线为 115.50 美元，200 日移动平均线为 113.64 美元。雅培的 12 个月低点为 99.71 美元，12 个月高点为 129.85 美元。该股票的市值为 2207.6 亿美元，市盈率为 16.64，PEG 比率为 2.51，贝塔值为 0.73。该公司的流动比率为 1.60，速动比率为 1.14，债务股本比率为 0.32。</p>
<ul>
<li>MarketBeat 周回顾 – 10/14 - 10/18</li>
</ul>
<p>雅培（NYSE:ABT - 获取免费报告）在 2023 年 1 月 22 日发布了季度财报。该医疗产品制造商报告每股收益（EPS）为 1.34 美元，符合市场共识预期的 1.34 美元。该公司在本季度的收入为 109.7 亿美元，而分析师预期为 110.3 亿美元。雅培的净利润率为 31.95%，股本回报率为 20.74%。与去年同期相比，雅培的收入增长了 7.2%。去年同期，该公司每股收益为 1.19 美元。卖方分析师预计雅培在当前财政年度的每股收益将达到 5.15 美元。</p>
<h2>雅培增加股息</h2>
<p>该公司最近还披露了季度股息，将于 2024 年 2 月 14 日支付。2024 年 1 月 15 日的股东将获得每股 0.59 美元的股息。该股息的除息日期为 2024 年 1 月 15 日。这比雅培之前的季度股息 0.55 美元有所增加。这相当于每年 2.36 美元的股息，股息收益率为 1.85%。雅培的派息比率目前为 30.85%。</p>
<h2>雅培公司简介</h2>
<p>（免费报告）</p>
<p>雅培及其子公司在全球范围内发现、开发、制造和销售医疗产品。它分为四个部门：成熟药品、诊断产品、营养产品和医疗器械。该公司提供用于治疗胰腺外分泌功能不全、肠易激综合症或胆道痉挛、肝内胆汁淤积或抑郁症状、妇科疾病、激素替代疗法、血脂异常、高血压、甲状腺功能减退、梅尼埃病和前庭眩晕、疼痛、发热、炎症和偏头痛的仿制药，以及提供抗感染药物克拉霉素、流感疫苗和调节结肠生理节律的产品。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票，胜过雅培</li>
<li>揭示 VWAP 的力量：交易者的关键指标</li>
<li>调查显示：2025 年远程工作者和商业交易的 150 家最佳咖啡店</li>
<li>如何最有效地使用 MarketBeat 财报筛选器</li>
<li>艾利 Lilly 的未来会怎样？</li>
<li>安静期到期的解释</li>
<li>甲骨文股票下跌近 14%——现在是买入的时机吗？</li>
</ul>
<p><strong>想看看其他对雅培持有股份的对冲基金吗？</strong> 访问 HoldingsChannel.com，获取雅培（NYSE:ABT - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在雅培吗？</h2>
<p>在考虑雅培之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而雅培并不在名单上。</p>
<p>虽然雅培目前在分析师中获得了 “适度买入” 的评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

雅培

<p>Orca Wealth Management LLC 在第四季度收购了雅培（NYSE:ABT）的新头寸，购买了 2,548 股，价值约为 288,000 美元。其他机构投资者也增加了对雅培的持股。分析师们提高了该股票的目标价，平均目标为 133.06 美元，市场共识评级为 “适度买入”。雅培的股票开盘价为 127.28 美元，市值为 2207.6 亿美元。该公司最近报告每股收益为 1.34 美元，并宣布将股息提高至每股 0.59 美元，股息将在 2 月 14 日支付</p>

<p>Orca Wealth Management LLC bought a new position in Abbott Laboratories (NYSE:ABT - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 2,548 shares of the healthcare product maker's stock, valued at approximately $288,000.</p>
<div class="lb-trans"><p>根据 Orca Wealth Management LLC 最近向证券交易委员会（SEC）提交的 13F 表格，该公司在第四季度购买了雅培（NYSE:ABT - 免费报告）的新头寸。该公司购买了 2,548 股该医疗产品制造商的股票，价值约为 288,000 美元。</p>
</div><p>Get <strong>Abbott Laboratories</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>雅培</strong> 的提醒：</p>
</div><ul>
<li>Abbott Laboratories Will Outperform Healthcare Stocks in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>雅培将在 2025 年超越医疗股票</li>
</ul>
</div><p>Other institutional investors and hedge funds also recently bought and sold shares of the company. Bath Savings Trust Co lifted its stake in shares of Abbott Laboratories by 3.7% during the 4th quarter. Bath Savings Trust Co now owns 166,132 shares of the healthcare product maker's stock valued at $18,791,000 after buying an additional 5,881 shares in the last quarter. Simplify Asset Management Inc. boosted its stake in shares of Abbott Laboratories by 67.3% during the 3rd quarter. Simplify Asset Management Inc. now owns 14,083 shares of the healthcare product maker's stock worth $1,606,000 after purchasing an additional 5,664 shares during the period. Pensionfund Sabic bought a new position in shares of Abbott Laboratories during the fourth quarter valued at approximately $2,828,000. Sequoia Financial Advisors LLC increased its stake in Abbott Laboratories by 19.6% in the third quarter. Sequoia Financial Advisors LLC now owns 193,764 shares of the healthcare product maker's stock worth $22,091,000 after purchasing an additional 31,720 shares during the period. Finally, Tidal Investments LLC lifted its holdings in Abbott Laboratories by 30.5% during the 3rd quarter. Tidal Investments LLC now owns 107,308 shares of the healthcare product maker's stock valued at $12,234,000 after buying an additional 25,052 shares in the last quarter. 75.18% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他机构投资者和对冲基金最近也买卖了该公司的股票。Bath Savings Trust Co 在第四季度将其在雅培的股份提高了 3.7%。Bath Savings Trust Co 现在拥有 166,132 股雅培的股票，价值为 18,791,000 美元，此前在上个季度又购买了 5,881 股。Simplify Asset Management Inc.在第三季度将其在雅培的股份提高了 67.3%。Simplify Asset Management Inc.现在拥有 14,083 股雅培的股票，价值为 1,606,000 美元，此前在此期间又购买了 5,664 股。Pensionfund Sabic 在第四季度购买了雅培的新头寸，价值约为 2,828,000 美元。Sequoia Financial Advisors LLC 在第三季度将其在雅培的股份增加了 19.6%。Sequoia Financial Advisors LLC 现在拥有 193,764 股雅培的股票，价值为 22,091,000 美元，此前在此期间又购买了 31,720 股。最后，Tidal Investments LLC 在第三季度将其在雅培的持股提高了 30.5%。Tidal Investments LLC 现在拥有 107,308 股雅培的股票，价值为 12,234,000 美元，此前在上个季度又购买了 25,052 股。目前，75.18% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>A number of equities analysts have recently issued reports on ABT shares. Morgan Stanley increased their price target on Abbott Laboratories from $107.00 to $117.00 and gave the stock an &#34;equal weight&#34; rating in a research report on Thursday, October 17th. Mizuho raised their price target on Abbott Laboratories from $115.00 to $130.00 and gave the stock a &#34;neutral&#34; rating in a report on Thursday, October 17th. Barclays reiterated an &#34;overweight&#34; rating and issued a $158.00 target price (up from $149.00) on shares of Abbott Laboratories in a research note on Monday. Jefferies Financial Group lifted their price objective on shares of Abbott Laboratories from $120.00 to $125.00 and gave the stock a &#34;hold&#34; rating in a research note on Thursday, October 17th. Finally, Raymond James reiterated a &#34;buy&#34; rating and set a $129.00 price objective (up from $122.00) on shares of Abbott Laboratories in a research note on Monday, October 14th. Four investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of &#34;Moderate Buy&#34; and an average price target of $133.06.</p>
<div class="lb-trans"><p>一些股票分析师最近对 ABT 股票发布了报告。摩根士丹利在 2023 年 10 月 17 日的研究报告中将雅培的目标价从 107.00 美元提高到 117.00 美元，并给予该股票 “持平” 评级。瑞穗在 2023 年 10 月 17 日的报告中将雅培的目标价从 115.00 美元提高到 130.00 美元，并给予该股票 “中性” 评级。巴克莱在周一的研究报告中重申了 “增持” 评级，并将雅培的目标价从 149.00 美元上调至 158.00 美元。杰富瑞金融集团在 2023 年 10 月 17 日的研究报告中将雅培的目标价从 120.00 美元提高到 125.00 美元，并给予该股票 “持有” 评级。最后，雷蒙德·詹姆斯在 2023 年 10 月 14 日的研究报告中重申了 “买入” 评级，并将雅培的目标价从 122.00 美元上调至 129.00 美元。四位投资分析师对该股票给予了持有评级，十三位分析师给予了买入评级。根据 MarketBeat.com 的数据，该公司的平均评级为 “适度买入”，平均目标价为 133.06 美元。</p>
</div><ul>
<li>These Are The Top Health Stocks to Own for Buy-and-Hold Investing</li>
</ul>
<div class="lb-trans"><ul>
<li>这些是值得持有的顶级健康股票</li>
</ul>
</div><p><strong>Check Out Our Latest Analysis on Abbott Laboratories</strong></p>
<div class="lb-trans"><p><strong>查看我们对雅培的最新分析</strong></p>
</div><h2>Abbott Laboratories Stock Performance</h2>
<div class="lb-trans"><h2>雅培股票表现</h2>
</div><p>NYSE ABT opened at $127.28 on Wednesday. The stock has a 50-day moving average of $115.50 and a 200 day moving average of $113.64. Abbott Laboratories has a twelve month low of $99.71 and a twelve month high of $129.85. The stock has a market capitalization of $220.76 billion, a price-to-earnings ratio of 16.64, a PEG ratio of 2.51 and a beta of 0.73. The company has a current ratio of 1.60, a quick ratio of 1.14 and a debt-to-equity ratio of 0.32.</p>
<div class="lb-trans"><p>雅培（NYSE ABT）周三开盘价为 127.28 美元。该股票的 50 日移动平均线为 115.50 美元，200 日移动平均线为 113.64 美元。雅培的 12 个月低点为 99.71 美元，12 个月高点为 129.85 美元。该股票的市值为 2207.6 亿美元，市盈率为 16.64，PEG 比率为 2.51，贝塔值为 0.73。该公司的流动比率为 1.60，速动比率为 1.14，债务股本比率为 0.32。</p>
</div><ul>
<li>MarketBeat Week in Review – 10/14 - 10/18</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 周回顾 – 10/14 - 10/18</li>
</ul>
</div><p>Abbott Laboratories (NYSE:ABT - Get Free Report) last released its quarterly earnings data on Wednesday, January 22nd. The healthcare product maker reported $1.34 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.34. The firm had revenue of $10.97 billion during the quarter, compared to analysts' expectations of $11.03 billion. Abbott Laboratories had a net margin of 31.95% and a return on equity of 20.74%. Abbott Laboratories's revenue was up 7.2% compared to the same quarter last year. During the same period last year, the business earned $1.19 earnings per share. Sell-side analysts anticipate that Abbott Laboratories will post 5.15 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>雅培（NYSE:ABT - 获取免费报告）在 2023 年 1 月 22 日发布了季度财报。该医疗产品制造商报告每股收益（EPS）为 1.34 美元，符合市场共识预期的 1.34 美元。该公司在本季度的收入为 109.7 亿美元，而分析师预期为 110.3 亿美元。雅培的净利润率为 31.95%，股本回报率为 20.74%。与去年同期相比，雅培的收入增长了 7.2%。去年同期，该公司每股收益为 1.19 美元。卖方分析师预计雅培在当前财政年度的每股收益将达到 5.15 美元。</p>
</div><h2>Abbott Laboratories Increases Dividend</h2>
<div class="lb-trans"><h2>雅培增加股息</h2>
</div><p>The business also recently disclosed a quarterly dividend, which will be paid on Friday, February 14th. Stockholders of record on Wednesday, January 15th will be given a dividend of $0.59 per share. The ex-dividend date of this dividend is Wednesday, January 15th. This is an increase from Abbott Laboratories's previous quarterly dividend of $0.55. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.85%. Abbott Laboratories's payout ratio is currently 30.85%.</p>
<div class="lb-trans"><p>该公司最近还披露了季度股息，将于 2024 年 2 月 14 日支付。2024 年 1 月 15 日的股东将获得每股 0.59 美元的股息。该股息的除息日期为 2024 年 1 月 15 日。这比雅培之前的季度股息 0.55 美元有所增加。这相当于每年 2.36 美元的股息，股息收益率为 1.85%。雅培的派息比率目前为 30.85%。</p>
</div><h2>Abbott Laboratories Profile</h2>
<div class="lb-trans"><h2>雅培公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.</p>
<div class="lb-trans"><p>雅培及其子公司在全球范围内发现、开发、制造和销售医疗产品。它分为四个部门：成熟药品、诊断产品、营养产品和医疗器械。该公司提供用于治疗胰腺外分泌功能不全、肠易激综合症或胆道痉挛、肝内胆汁淤积或抑郁症状、妇科疾病、激素替代疗法、血脂异常、高血压、甲状腺功能减退、梅尼埃病和前庭眩晕、疼痛、发热、炎症和偏头痛的仿制药，以及提供抗感染药物克拉霉素、流感疫苗和调节结肠生理节律的产品。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Abbott Laboratories</li>
<li>Unveiling The Power Of VWAP: A Key Indicator For Traders</li>
<li>Survey Reveals: Top 150 Best Coffee Shops for Remote Workers and Business Deals [2025]</li>
<li>How to Most Effectively Use the MarketBeat Earnings Screener</li>
<li>What Does the Future Hold for Eli Lilly?</li>
<li>Quiet Period Expirations Explained</li>
<li>Oracle Stock Drops Nearly 14% – Is Now the Time to Buy?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过雅培</li>
<li>揭示 VWAP 的力量：交易者的关键指标</li>
<li>调查显示：2025 年远程工作者和商业交易的 150 家最佳咖啡店</li>
<li>如何最有效地使用 MarketBeat 财报筛选器</li>
<li>艾利 Lilly 的未来会怎样？</li>
<li>安静期到期的解释</li>
<li>甲骨文股票下跌近 14%——现在是买入的时机吗？</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding ABT?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对雅培持有股份的对冲基金吗？</strong> 访问 HoldingsChannel.com，获取雅培（NYSE:ABT - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=ABT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Abbott Laboratories Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在雅培吗？</h2>
</div><p>Before you consider Abbott Laboratories, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑雅培之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abbott Laboratories wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而雅培并不在名单上。</p>
</div><p>While Abbott Laboratories currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然雅培目前在分析师中获得了 “适度买入” 的评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Orca Wealth Management LLC 在雅培公司（NYSE:ABT）中获得了新的头寸